Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Regeneron Pharmaceuticals Comprehensive Income (Loss), Net of Tax, Attributable to Parent decreased by 22.4% to $661.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 21.8%, from $845.70M to $661.60M. Over 4 years (FY 2021 to FY 2025), Comprehensive Income (Loss), Net of Tax, Attributable to Parent shows a downward trend with a -13.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Higher values indicate stronger overall financial performance and equity growth for the parent company.
Detailed definition
This represents the total comprehensive income or loss attributable specifically to the parent company's shareholders af...
Peer comparison
Standard financial reporting metric used by all public companies to show total equity changes.
other_comprehensive_income_net_of_taxHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.10B | $1.63B | $2.19B | $829.60M | $798.40M | $1.26B | $1.23B | $875.00M | $952.30M | $1.03B | $1.26B | $725.70M | $1.44B | $1.47B | $849.60M | $845.70M | $1.42B | $1.48B | $853.10M | $661.60M |
| QoQ Change | — | -47.5% | +34.9% | -62.2% | -3.8% | +58.4% | -2.5% | -29.1% | +8.8% | +8.0% | +22.0% | -42.2% | +98.4% | +2.2% | -42.2% | -0.5% | +67.3% | +4.3% | -42.2% | -22.4% |
| YoY Change | — | — | — | — | -74.2% | -22.2% | -43.8% | +5.5% | +19.3% | -18.6% | +1.8% | -17.1% | +51.2% | +43.0% | -32.3% | +16.5% | -1.7% | +0.4% | +0.4% | -21.8% |
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
- Regeneron Pharmaceuticals (REGN) reported comprehensive income (loss), net of tax, attributable to parent of $661.60M in Q1 2026.
- How has Regeneron Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Regeneron Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent decreased by 21.8% year-over-year, from $845.70M to $661.60M.
- What is the long-term trend for Regeneron Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent has grown at a -13.0% compound annual growth rate (CAGR), from $8.02B to $4.59B.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- The total comprehensive profit or loss belonging to the parent company's shareholders.